Innovators in DNA Repair
Cyteir is developing the next generation of synthetic lethal therapies to treat cancer
Cyteir Therapeutics is a leader in the discovery and development of novel therapeutics based on the biology of DNA repair and synthetic lethality for the treatment of cancer. Our initial approach takes advantage of DNA damage overload to induce selective self-destruction of cells by targeting disease-induced RAD51 activity.
Through precision targeting of key DNA repair factors, diseased cells with excessive DNA damage are induced to self-destruct by DNA damage overload.
With a new approach to the synthetic lethal paradigm we are developing novel drugs for use in a range of cancer types.
“The recent approval and development of PARP inhibitors has paved the way for additional novel DNA repair/synthetic lethality therapies to meet unmet clinical needs in cancers.”
Markus Renschler, MD
President and Chief Executive Officer, Cyteir Therapeutics, Inc.